SCHEMBL6358732

SCHEMBL6358732

c1ccc(OCc2c[nH]cn2)c(OCc2c[nH]cn2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
LTA4H P09960 1/20 0.37
MAPK14 Q16539 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HTR1A P08908 2/20 0.36
ABCB1 P08183 1/20 0.36
DRD2 P14416 1/20 0.36
SYK P43405 3/20 0.35
RAB9A P51151 2/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
IDO1 P14902 1/20 0.35
NPC1 O15118 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KCNH2 Q12809 1/20 0.34
AURKB Q96GD4 2/20 0.34
INCENP Q9NQS7 2/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL223566 0.91 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AHTR1ASYK
SCHEMBL224554 0.91 LTA4H (0.50) LTA4HMAPK14HTR1AABCB1DRD2
SCHEMBL226843 0.88 NISCH (0.48) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL224611 0.88 TP53 (0.45) ALDH1A1MEN1KMT2ASYKRAB9A
SCHEMBL224876 0.88 MEN1 (0.44) ALDH1A1MEN1KMT2ASYKMAPK1
SCHEMBL224997 0.88 GAA (0.47) ALDH1A1DRD2SMN1; SMN2LMNAAPP
SCHEMBL223663 0.87 RXRA (0.46) ALDH1A1DRD2
SCHEMBL224978 0.87 NISCH (0.51) ALDH1A1MEN1KMT2AHTR1ASMN1; SMN2
SCHEMBL222619 0.85 NISCH (0.50) MEN1KMT2AHTR1AABCB1DRD2
SCHEMBL225470 0.85 ADRA1D (0.55) ALDH1A1MEN1KMT2ASYKRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317068-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION OHIO UNIVERSITY 2021-10-14 US disclosed
US-11072576-B2 Compositions and methods for glucose transport inhibition OHIO UNIVERSITY (US) 2021-07-27 US disclosed
US-20190345094-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION OHIO UNIVERSITY 2019-11-14 US disclosed
US-10385005-B2 Compositions and methods for glucose transport inhibition OHIO UNIVERSITY (US) 2019-08-20 US disclosed
US-10000443-B2 Compositions and methods for glucose transport inhibition OHIO UNIVERSITY (US) 2018-06-19 US disclosed
US-10000443-B2 Compositions and methods for glucose transport inhibition OHIO UNIVERSITY (US) 2018-06-19 US disclosed
US-20160137585-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION OHIO UNIVERSITY (US) 2016-05-19 US disclosed
US-9181162-B2 Compositions and methods for glucose transport inhibition OHIO UNIVERSITY (US) 2015-11-10 US disclosed
US-20120121536-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION OHIO UNIVERSITY (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317068-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION SLC2A1, SLC2A4, SLC2A3 ALDH1A1 2181/4885LTA4H 3747/4885MAPK14 1360/4885
US-20160137585-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION SLC2A1, SLC2A4, SLC2A3 ALDH1A1 2181/4885LTA4H 3747/4885MAPK14 1360/4885
US-10385005-B2 Compositions and methods for glucose transport inhibition SLC2A1, SLC2A4, SLC2A3 ALDH1A1 2181/4885LTA4H 3747/4885MAPK14 1360/4885
US-20190345094-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION SLC2A1, SLC2A4, SLC2A3 ALDH1A1 2181/4885LTA4H 3747/4885MAPK14 1360/4885
US-11072576-B2 Compositions and methods for glucose transport inhibition SLC2A1, SLC2A4, SLC2A3 ALDH1A1 2181/4885LTA4H 3747/4885MAPK14 1360/4885
US-20120121536-A1 COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION SLC2A1, SLC2A4, SLC2A3 ALDH1A1 2181/4885LTA4H 3747/4885MAPK14 1360/4885
US-10000443-B2 Compositions and methods for glucose transport inhibition SLC2A1, SLC2A4, SLC2A3 ALDH1A1 2181/4885LTA4H 3747/4885MAPK14 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.